Theratechnologies Says FDA Approved Labelling Prior Approval Supplement To Include A 2000-mg Intravenous (IV) Push Loading Dose For Trogarzo (ibalizumab-uiyk)
Portfolio Pulse from Benzinga Newsdesk
Theratechnologies announced that the FDA has approved a label update for Trogarzo to include a 2000-mg IV push loading dose. Trogarzo (ibalizumab-uiyk) is used in the treatment of HIV.
December 13, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Theratechnologies' Trogarzo receives FDA approval for a new IV push loading dose, potentially improving patient convenience and treatment uptake.
FDA approval of a new dosage form for a drug typically leads to increased market adoption and can be a positive catalyst for the company's stock. The approval for a 2000-mg IV push loading dose of Trogarzo may lead to improved patient adherence and convenience, which could increase the drug's usage and sales. As the company directly responsible for Trogarzo, Theratechnologies is likely to experience a positive impact on its stock price in the short term due to this regulatory milestone.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100